Basilea Revenue and Competitors

Basel,

Location

N/A

Total Funding

Fintech

Industry

Estimated Revenue & Valuation

  • Basilea's estimated annual revenue is currently $34.6M per year.(i)
  • Basilea's estimated revenue per employee is $143,000

Employee Data

  • Basilea has 242 Employees.(i)
  • Basilea grew their employee count by -7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M26-4%$15.7MN/A
#2
$22.3M156-2%N/AN/A
#3
$1.4M21-50%$21.2MN/A
#4
$38.8M27119%$6MN/A
#5
$6M53-22%$216.8MN/A
#6
$0M1-50%$33.3MN/A
#7
$26M1820%N/AN/A
#8
$30.9M221-26%$64.6MN/A
#9
$28.6M205-22%$46.8MN/A
#10
$249.1M134015%$75MN/A
Add Company

Basilea is a revenue-generating, commercial-stage Swiss biotech company. Our activities are focused in the areas of oncology, hospital antibiotics and hospital antifungals. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and three oncology drug candidates in development. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 as a spin-out from Roche and is headquartered in the heart of the life sciences hub of Basel. The Basilea group currently has 220 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.

keywords:N/A

N/A

Total Funding

242

Number of Employees

$34.6M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A2848%N/A
#2
$38M28835%N/A
#3
$85.8M28930%N/A
#4
$57M294-7%$2.1B
#5
$93M33832%N/A

Basilea Executives


NameTitle
David VeitchChief Executive Officer